VEGF Trap in Treating Patients With Metastatic Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the breast * Clinical evidence of metastatic disease * No more than 2 prior chemotherapy regimens for metastatic disease * Prior neoadjuvant or adjuvant chemotherapy allowed\* * At least 1 prior regimen (in any setting) must have included a taxane and/or an anthracycline * Measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured per RECIST criteria * No nonmeasurable disease, defined as all other lesions, including small lesions(longest diameter \< 20 mm) and truly nonmeasurable lesions, including the following: * Bone lesions * Leptomeningeal disease * Ascites * Pleural/pericardial effusion * Inflammatory breast disease * Lymphangitis cutis/pulmonis * Abdominal masses that are not confirmed and followed by imaging techniques * Cystic lesions * Patients with HER2-positive tumors (3+ by immunohistochemistry or amplified by fluorescent in situ hybridization \[FISH\]) must have received ≥ 1 prior trastuzumab (Herceptin®)-containing regimen in either the adjuvant or metastatic setting, unless there was a contraindication * No known CNS metastases * No evidence of leptomeningeal involvement * Hormone receptor status not specified * Male or female * Menopausal status not specified * ECOG performance status 0-1 * Life expectancy \> 3 months * WBC ≥ 3,000/mm³ * Absolute neutrophil count ≥ 1,500/mm³ * Platelet count ≥ 75,000/mm³ * Hemoglobin \> 8.0 g/dL * Bilirubin ≤ 1.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN * AST and ALT ≤ 2.5 times ULN * Creatinine ≤ 1.5 times ULN * Urine protein:creatinine ratio \< 1 OR urine protein \< 500 mg by 24-hour urine collection * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 6 months after completion of study treatment * No significant traumatic injury within the past 4 weeks * No history of allergy or hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, drug product excipients, or agents chemically or biologically similar to VEGF Trap * No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days * No nonhealing wound, fracture, or ulcer * No stage III or IV invasive, nonbreast malignancy within the past 5 years * No history of lung carcinoma of squamous cell type * No clinically significant cardiovascular disease, including any of the following: * Cerebrovascular accident or stroke within the past 6 months * Uncontrolled hypertension, defined as blood pressure (BP) \> 150/100 mm Hg OR systolic BP \> 180 mm Hg if diastolic blood pressure \< 90 mm Hg on ≥ 2 separate occasions within the past 3 months * Myocardial infarction, coronary artery bypass graft, or unstable angina within the past 6 months * New York Heart Association class III or IV cardiovascular disease * Serious cardiac arrhythmia requiring medication * Peripheral vascular disease ≥ grade 2 within the past 6 months * Pulmonary embolism, deep vein thrombosis, or other thromboembolic event within the past 6 months * No evidence of bleeding diathesis or uncontrolled coagulopathy * No active, unresolved infection * No serious concurrent medical condition that would preclude study participation * No other condition or circumstance that would preclude compliance with study requirements * See Disease Characteristics * Prior hormonal therapy in the neoadjuvant, adjuvant, or metastatic setting allowed * No prior bevacizumab * More than 4 weeks since prior chemotherapy, endocrine therapy, experimental drug therapy, or immunotherapy and recovered * More than 4 weeks since prior major surgery or open biopsy * More than 7 days since prior core biopsy * More than 2 weeks since prior radiotherapy, except if to a nontarget lesion only * Prior radiotherapy to a target lesion allowed only if there has been clear progression of the lesion since radiotherapy was completed * Prior single-dose palliative radiotherapy within the past 2 weeks allowed * No concurrent major surgery * No concurrent trastuzumab * Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR \> 1.5 allowed provided the following criteria are met: * INR in-range (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin * No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) * No concurrent combination antiretroviral therapy for HIV-positive patients * No concurrent participation in another investigational clinical trial * No other concurrent chemotherapeutic agents, endocrine therapy, biologic agents, radiotherapy, or other nonprotocol antitumor therapy